About Us

---

 Our  mission is to significantly improve the prevention and treatment of  microbial infections. In particular, we are focused on increasing the  treatment options for people infected with the Staphylococcus aureus(S. aureus).  The technology we have developed has particular application for the  treatment and prevention of infections by antibiotic resistant strains  of S. aureus. A key target population for our technology is the group of individuals at increased risk of exposure to and infection by S. aureus strains, especially antibiotic resistant strains such as  methicillin-resistant strains (MRSA), vancomycin-intermediate strains  (VISA) and vancomycin-resistant strains (VRSA). ImmLab technology would  have a role for pre-treatment of those facing elective surgery or any  other non-urgent invasive treatment.  

In addition to use in  human populations, ImmLab’s products have important application in the  dairy industry by providing a non-antibiotic option for preventing  staphylococcal infection of the udder (mastitis) in calves, before the  calves reach a productive age. Additional non-human uses include the use  of ImmLab’s products for treatment of S. aureus skin infections in small animals, including companions and fur bearing animals. 

We  are dedicated to using our technology platform to extend the  applications and products to treatment and prevention of infections such  as a new emerging staphylococcal strain ST398 and other bacterial  strains according to actual epidemiological situation.  The technology  and product line being developed by ImmLab will not only improve the  health and well-being of people and animals subject to microbial  infection, but will do so using an approach that will not add to the  growing threat of antibiotic resistant bacterial strains. 

Immlab’s  technologies make it possible to manufacture novel preparations that  contain biologically active components derived from S. aureus.  The biologically active components in ImmLab's therapeutic preparations  activate both innate and acquired immunity, including humoral and  cell-mediated responses. Treatments with ImmLab’s preparations are  efficient, cost-effective and may easily be carried out with nasal drops  or injections for human use, as well as injections for animal  use. Therefore, ImmLab’s commitment is to improve the diagnostics,  treatment and prevention of bacterial infections.  ImmLab will provide  innovative, practical and top-quality products that will improve the  health of humans and animals suffering from life threatening infections  due to existing and emerging antibiotic-resistant bacterial strains.